Analysts Offer Predictions for Mediwound Ltd’s FY2018 Earnings (NASDAQ:MDWD)

Mediwound Ltd (NASDAQ:MDWD) – Equities research analysts at Jefferies Financial Group lifted their FY2018 EPS estimates for Mediwound in a research report issued to clients and investors on Wednesday, November 14th, according to Zacks Investment Research. Jefferies Financial Group analyst R. Denhoy now expects that the biopharmaceutical company will earn ($0.57) per share for the year, up from their previous estimate of ($0.64). Jefferies Financial Group also issued estimates for Mediwound’s Q1 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.15) EPS and Q4 2019 earnings at ($0.14) EPS.

A number of other equities analysts have also recently commented on MDWD. Zacks Investment Research raised Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday, October 25th. ValuEngine raised Mediwound from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. Oppenheimer set a $14.00 target price on Mediwound and gave the company a “buy” rating in a research note on Wednesday, November 14th. Finally, Wells Fargo & Co set a $11.00 target price on Mediwound and gave the company a “buy” rating in a research note on Wednesday, August 8th.

Mediwound stock traded down $0.01 during trading hours on Monday, reaching $5.68. The company had a trading volume of 23,719 shares, compared to its average volume of 14,402. The stock has a market capitalization of $156.07 million, a P/E ratio of -9.16 and a beta of -0.03. Mediwound has a 12-month low of $3.56 and a 12-month high of $7.35.

Mediwound (NASDAQ:MDWD) last announced its quarterly earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.08. The business had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $1.05 million. Mediwound had a negative return on equity of 400.37% and a negative net margin of 477.34%.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in shares of Mediwound by 10.4% during the second quarter. Renaissance Technologies LLC now owns 130,500 shares of the biopharmaceutical company’s stock valued at $900,000 after buying an additional 12,300 shares during the period. Wells Fargo & Company MN increased its stake in shares of Mediwound by 19.9% during the first quarter. Wells Fargo & Company MN now owns 121,323 shares of the biopharmaceutical company’s stock valued at $631,000 after buying an additional 20,134 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Mediwound by 1.0% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company’s stock valued at $14,478,000 after buying an additional 21,559 shares during the period. Nexthera Capital LP purchased a new position in shares of Mediwound during the second quarter valued at approximately $308,000. Finally, Worth Venture Partners LLC purchased a new position in shares of Mediwound during the third quarter valued at approximately $306,000. 31.93% of the stock is currently owned by hedge funds and other institutional investors.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Further Reading: Candlestick

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply